Investigational drug · Phase 3
Icotinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
103
Any phase or sponsor naming "Icotinib"
First trial start
2023
Mar 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Icotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- EGFR Sensitive Mutation
- Adjuvant Therapy
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Icotinib" as an intervention, largest first.
Betta Pharmaceuticals Co., Ltd.Industry
NCT07806604 · 2,572 participants (planned) · Start Sep 2026 · Primary completion Feb 2027
Drug: Icotinib · For: NSCLC (Non-small Cell Lung Cancer)
Sites: Beijing, China; Shanghai, China
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyPivotal-lookingStatus unknown
Tian XieAcademic, hospital or other
NCT04401059 · 744 participants (planned) · Start Nov 9, 2020 · Primary completion Sep 30, 2025
Drug: Elemene plus first or third generation EGFR-TKIs; First or third generation EGFR-TKIs · For: Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma
Sites: Nantong, China; Panjin, China; Shanghai, China · 7 sites in all
- EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02714010 · 601 participants (planned) · Start Aug 2015 · Primary completion Dec 2021
Drug: EGFR-TKI · For: Non-Small Cell Lung Cancer
Sites: Guangzhou, China
- Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsPivotal-lookingRecruiting
Betta Pharmaceuticals Co., Ltd.Industry
NCT06041776 · 570 participants (planned) · Start Mar 28, 2023 · Primary completion Apr 30, 2028
Drug: Befotertinib + Icotinib placebo; Icotinib + Befotertinib placebo · For: Non-Small Cell Lung Cancer; EGFR Sensitive Mutation; Adjuvant Therapy
Sites: Beijing, China; Nanjing, China; Shanghai, China
- Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary AdenocarcinomaStatus unknown
Shanghai University of Traditional Chinese MedicineAcademic, hospital or other
NCT01745302 · 470 participants (planned) · Start Nov 2011 · Primary completion Dec 2016
Drug: TCM; EGFR-TKI · For: Cancer
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsPivotal-lookingCompleted
Betta Pharmaceuticals Co., Ltd.Industry
NCT01040780 · 399 participants · Start Feb 2009 · Primary completion Mar 2010
Drug: Icotinib; Gefitinib · For: Non-small Cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 27 sites in all
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCPivotal-lookingCompleted
Betta Pharmaceuticals Co., Ltd.Industry
NCT04206072 · 362 participants · Start Dec 24, 2019 · Primary completion Jul 30, 2022
Drug: D-0316 Capsule; Icotinib Hydrochloride Tablets · For: Non-Small Cell Lung Cancer; EGFR Gene Mutation
Sites: Hangzhou, China; Liuzhou, China
- First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationPivotal-lookingStatus unknown
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAcademic, hospital or other
NCT02883543 · 330 participants (planned) · Start Jun 2016 · Primary completion Jun 2018
Drug: icotinib; Chemotherapy · For: Non-small Cell Lung Cancer
- Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)Pivotal-lookingStatus unknown
Sichuan Provincial People's HospitalAcademic, hospital or other
NCT02882984 · 325 participants (planned) · Start Mar 2015 · Primary completion Mar 2020
Drug: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib · For: Stage IV EGFR Mutated NSCL With Brain Metastases
Sites: Chengdu, China
- Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationPivotal-lookingStatus unknown
Betta Pharmaceuticals Co., Ltd.Industry
NCT02448797 · 320 participants (planned) · Start Jun 8, 2015 · Primary completion Jun 30, 2022
Drug: Icotinib; Chemotherapy · For: Non-small Cell Lung Cancer
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review.
Huang H, Song L, Tong F, et al. · Front Oncol 2026
- Comparative Efficacy of First-Line versus Further-Line Icotinib Therapy in Advanced Lung Adenocarcinoma: A Real-World Cohort Study.
Zhang X, Wang J, Chen J · Onco Targets Ther 2026
- Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report.
Niu Z, Zhu Y, Zhou Y, et al. · Front Pharmacol 2026
- Pleural Fluid Cytology Detects Small Cell Carcinoma Transformation in EGFR-Mutant Lung Adenocarcinoma: A Case Report.
Zhou H, He Z, Wang Z, et al. · Diagn Cytopathol 2026
- Exosomal circ_0097112 drives icotinib resistance through activating RAF/MAPK signaling in lung adenocarcinoma.
Chen Z, Wang Y, Xu Y, et al. · Cell Signal 2026
- Clinical Efficacy and Safety of Icotinib as Adjuvant Therapy for Resected Stage IA Lung Adenocarcinoma: A Real-world Study.
Luo SS, Zhong LQ, Liu X, et al. · Clin Lung Cancer 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.